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Background/Aims: Yes-associated protein (YAP) and transcriptional co-activator with
PDZ-binding motif (TAZ) activation has been implicated in hepatocarcinogenesis and
hepatic progenitor cell differentiation, and hypoxia has been shown to induce nuclear
translocation of YAP in cancer cells. Here, we aimed to investigate the relationship between
hypoxia, YAP and TAZ expression and stemness-related marker expression in human
hepatocellular carcinomas (HCCs) and its clinical implications.
Methods: Immunohistochemical stains were performed on tissue microarrays from 305
surgically resected HCCs, and the expression status of YAP and TAZ were correlated with
CAIX, stemness markers (K19, EpCAM) and epithelial-mesenchymal transition (EMT)-
related markers (uPAR, ezrin). The clinicopathological significance of YAP/TAZ expression
was analyzed with relation to CAIX expression status.
Results: YAP and TAZ expression were seen in 13.4 and 4.3% of HCCs, respectively.
YAP/TAZ-positive HCCs frequently demonstrated higher serum AFP levels, microvascular
invasion, advanced tumor stage, increased proliferative activity and expression of
stemness- and EMT-related markers, CAIX, p53 and Smad2/3 (p < 0.05, all).
Interestingly, YAP/TAZ-positivity was associated with microvascular invasion, higher
serum AFP levels, stemness and EMT-related marker expression only in tumors
expressing CAIX (p < 0.05, all), while these associations were not seen in CAIX-
negative HCCs.
Conclusions: YAP/TAZ expression is associated with vascular invasion, stemness and
EMT in HCCs with hypoxia marker expression. The effect of Hippo signaling pathway









†These authors share first authorship
Received: 09 September 2020
Accepted: 12 January 2021
Published: 01 March 2021
Citation:
Park H, Lee Y, Lee K, Lee H, Yoo JE,
Ahn S, Park YN and Kim H (2021) The
Clinicopathological Significance of
YAP/TAZ Expression in Hepatocellular
Carcinoma with Relation to Hypoxia
and Stemness.
Pathol. Oncol. Res. 27:604600.
doi: 10.3389/pore.2021.604600
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; AFP, alpha-feto-
protein; CAIX, carbonic anhydrase-IX; K19, keratin 19; EpCAM, epithelial cell adhesion molecule; uPAR, urokinase-type
plasminogen activator receptor.







published: 01 March 2021
doi: 10.3389/pore.2021.604600
microenvironment, and hypoxia marker expression status should be taken into account
when considering the use of YAP/TAZ as markers of aggressive biologic behavior in HCC.
Keywords: hepatocellular carcinoma, Hippo pathway, hypoxia, stemness, immunohistochemistry
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common
malignancy worldwide and the fourth leading cause of cancer-
related deaths. A subset of HCCs (5–20%) have been
demonstrated to express markers associated with “stemness,”
including keratin 19 (K19), epithelial cell adhesion molecule
(EpCAM), CD133, CD117/c-kit and SALL4, and these HCCs
have been associated with aggressive biological behavior and poor
survival [1]. The molecular features of stemness-related marker-
expressing HCCs are still not well understood – so far, this group
of HCCs has been placed in the G1, S2 and proliferation class
molecular subgroups, and TP53 mutations, transforming growth
factor (TGF)-β and Notch signaling pathways have been
implicated in these tumors [2–4]. Even though the prognostic
relevance of stemness-related marker expression has been
increasingly recognized over the recent years, the lack of
therapeutic options for this particular subset of HCCs is still a
point of concern.
The Hippo pathway controls tissue homeostasis, including
organ size, cell proliferation and apoptosis [5, 6]. The
oncoproteins Yes-associated protein (YAP) and
transcriptional co-activator with PDZ-binding motif (TAZ)
are downstream components of this pathway, and deregulation
of the Hippo pathway with activation of YAP and TAZ has
been implicated in carcinogenesis, including HCC
development [7, 8]. For example, sav1 knockout mice have
been shown to develop HCC through the activation of YAP [9].
Activated YAP has been associated with aggressive behavior of
various malignant neoplasms, including cell proliferation,
stemness, epithelial-mesenchymal transition (EMT) and
chemoresistance [10–14]. YAP protein expression has been
demonstrated in stemness-marker expressing HCCs and in
combined hepatocellular-cholangiocarcinomas, both of which
have been postulated to show features of hepatic progenitor
cell differentiation [11, 15].
Hypoxia has been associated with aggressive tumor behavior
[16]. HCC is no exception; the rapid growth and the relative lack
of blood supply results in a hypoxic microenvironment, and
HCCs adapt to this unfavorable condition by expressing hypoxia-
inducible factors, such as HIF1α and carbonic anhydrase-IX
(CAIX) [17, 18]. Associations between CAIX expression,
stemness-related marker expression and aggressive
clinicopathological features have been seen in HCCs [19]. In
addition, hypoxia has been demonstrated to induce YAP nuclear
translocation in cancer cells [20]. Therefore, we sought out to
investigate the relationship between hypoxia, YAP/TAZ
expression and stemness-related marker expression and the




Three hundred and five HCCs that were surgically resected
between 2003 and 2012 at Seoul National University Bundang
Hospital (SNUBH), Seongnam, Republic of Korea were evaluated
in this study. This study was approved by the Institutional Review
Board of SNUBH (B-1704-391-301), and informed consent was
waived due to the retrospective nature of the study. The
clinicopathological information was prospectively recorded by
reviewing the electronic medical records, including patient age,
sex, underlying etiology, serum alpha-fetoprotein (AFP) levels,
preoperative locoregional treatment (including radiofrequency
ablation, transarterial chemo/radioembolization), tumor size,
gross type [21], multiplicity, histologic grade (Edmonson-
Steiner), major vascular and microvascular invasion status, and
pathological T and N stages according to American Joint
Committee on Cancer (AJCC) 8th edition. Multiplicity was
defined as 2 or more tumors, and included intrahepatic
metastases and multicentric occurrences. Major vascular
invasion was defined as invasion of the main portal vein and
first-order branches, the right, middle and left hepatic veins, or
the right or left hepatic artery. Microvascular invasion was
defined as invasion of smaller caliber vessels by tumor cells;
the microvessels were located in the tumor capsule or in the
peritumoral non-neoplastic liver, and were not portal vein,
hepatic veins or hepatic arteries [22]. The presence of
intratumoral fibrous stroma was recorded: fibrous stroma
exceeding 10% of the tumor area was regarded as “present.”
For the background liver, the fibrosis stage was recorded
according to the METAVIR system.
We defined disease-free survival as the interval from surgical
treatment to the date of disease recurrence (local recurrence or
intrahepatic/distant metastasis). Overall survival was defined as
the interval between surgical treatment and date of death from
HCC or other causes.
Tissue Microarray and
Immunohistochemistry
Tissue microarray cores of 2 mm-diameter were obtained from the
305 SNUBH HCCs (SuperBioChips Laboratory, Seoul, Korea).
One to three cores from the HCCs and matched non-neoplastic
liver were evaluated in this study. Immunohistochemical stains for
YAP, TAZ, K19, EpCAM, CAIX, p53, ezrin, urokinase-type
plasminogen activator receptor (uPAR), smad2/3 and Ki-67
were performed on 4 μm-thick tissue microarray sections
manually or by using the Ventana BenchMark GX automated
platform (VentanaMedical Systems). The details for each antibody
are summarized in Table 1.
Pathology & Oncology Research March 2021 | Volume 27 | Article 6046002
Park et al. YAP/TAZ Expression in HCC with Hypoxia
The presence of cytoplasmic expression in >5% of the tumor
cells was regarded as positive for K19, uPAR and smad2/3
expression. EpCAM, CAIX and ezrin were expressed in the
tumor cell membranes. Although YAP and TAZ were
expressed in both the cytoplasm and nuclei, only unequivocal
nuclear or nucleocytoplasmic staining for YAP and TAZ were
interpreted as positive. Cytoplasmic YAP/TAZ expression
without the nuclear stain was not counted as positive
regardless of the intensity. Strong nuclear p53 expression
in >5% of tumor cells was interpreted as p53 overexpression.
The Ki-67 labeling index was calculated as the percentage of
Ki-67-stained tumor cell nuclei over the total number of
nuclei in a ×400 magnification field, with the use of
ImageJ analysis software (downloaded from
imagej.nih.gov/ij, version 1.47).
Statistical Analysis
Statistical analysis was performed using STATA version 14.0
(StataCorp, College Station, TX, United States). The student
t-test was used for comparing continuous variables, and the
chi-square and Fisher-exact tests were used for categorical
variables. Survival analysis was performed by the Kaplan-
Meier method with the log-rank test. Statistical significance
was defined as a p-value of < 0.05.
TABLE 1 | List of antibodies used in this study.
Antibody (clone) Source Dilution Method
YAP (rabbit mAb; D8H1X) Cell Signaling (Danvers, MA, United States) 1:100 Autostainer (CC1, 32′/60′)
TAZ-WWTR1 (rabbit pAb) Merck (Darmstadt, Germany) 1:100 Autostainer (CC1, 32’/60′)
K19 (mouse mAb) Dako (Glostrup, Denmark) 1:200 Autostainer (CC1, 32′/60′)
EpCAM (mouse mAb; VU-1D9) Millipore (Temecula, United States) 1:1,500 Autostainer (CC1, 32’/30′)
CAIX (rabbit pAb) Abcam (Cambridge, United Kingdom) 1:500 Autostainer (CC1, 32’/60′)
p53 (mouse mAb; DO-7) Dako (Glostrup, Denmark) 1:1,000 Autostainer (CC1, 32’/16′)
ezrin (mouse mAb; 3C12) Abcam (Cambridge, United Kingdom) 1:100 Microwave, citrate (pH 6.0)
uPAR (mouse mAb) Abcam (Cambridge, United Kingdom) 1:40 Microwave, citrate (pH 6.0)
smad2/3 (mouse mAb; C-8) Santa Cruz (Dallas, United States) 1:500 Autostainer (CC1, 32’/60′)
Ki-67 (mouse mAb; MIB-1) Dako (Glostrup, Denmark) 1:100 Autostainer (CC1, 64’/16′)
FIGURE 1 | Immunohistochemical stain results. A representative YAP/TAZ-positive HCC showing abundant intratumoral fibrous stroma (A hematoxylin-eosin
stain, ×100; B,C YAP; D,E TAZ) showing expression of CAIX (F), K19 (G), EpCAM (H), ezrin (I), uPAR (J), p53 (K) and smad2/3 (L) (B,D,F–L ×200; C,E ×400).
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RESULTS
YAP/TAZ Expression Status in HCCs and
Non-Neoplastic Livers
In non-neoplastic livers, YAP and TAZ were both expressed in
the nuclei and cytoplasm of bile ducts and ductular reactions.
Hepatocytes were mostly negative for YAP and TAZ; however,
occasional periportal or periseptal hepatocytes demonstrated
weak nucleocytoplasmic YAP expression. In addition, YAP
and TAZ were expressed in endothelial cells. The presence of
nuclear stain was regarded as positive for both YAP and TAZ.
YAP and TAZ expression were seen in 41/305 (13.4%) and 13/
305 (4.3%) HCCs, respectively (Figure 1). There was a positive
correlation between YAP and TAZ expression status (p < 0.001)
TABLE 2 | Summary of the clinicopathological and immunohistochemical characteristics of HCCs according to YAP/TAZ and CAIX expression status.






















0.806 8 (100)/0 (0) 82 (67.8)/
29 (24.0)
0.197
Age (years) 56 (30–76) 59 (29–87) 0.260d 58 (30–76) 59 (29–83) 0.645d 53 (38–72) 59 (30–87) 0.236d
Etiology 0.694e 0.666e 0.799e
HBV 29 (78.4) 148 (67.9) 23 (79.3) 68 (70.1) 6 (75.0) 80 (66.1)
HCV 2 (5.4) 23 (10.6) 1 (3.4) 8 (8.2) 1 (12.5) 15 (12.4)
HBV + HCV 0 (0) 1 (0.5) 0 (0) 0 (0) 0 (0) 1 (0.8)
Alcohol 2 (5.4) 10 (4.6) 1 (3.4) 2 (2.1) 1 (12.5) 8 (6.6)
NAFLD 0 (0) 11 (5.0) 0 (0) 8 (8.2) 0 (0) 3 (2.5)
Unknown 4 (10.8) 25 (11.5) 4 (13.8) 11 (11.3) 0 (0) 4 (3.3)
Serum AFP level (≥400 ng/ml) 13 (35.1) 37 (17.0) 0.024 12 (71.4) 22 (22.7) 0.095 1 (12.5) 15 (12.4) 1.000
Preoperative locoregional treatment 12 (32.4) 69 (31.7) 0.849 8 (27.6) 32 (33.0) 0.819 4 (50.0) 37 (30.6) 0.264











Gross type 0.210 0.194 1.000
Vaguely nodular/expanding nodular 12 (32.4) 96 (44.0) 8 (27.6) 42 (43.3) 4 (50.0) 54 (44.6)
Multinodular confluent/nodular with
perinodular extension/infiltrative
25 (67.6) 121 (55.5) 21 (72.4) 55 (56.7) 4 (50.0) 66 (54.5)
Multiplicity (present) 8 (21.6) 36 (16.5) 0.481 6 (20.7) 18 (18.6) 0.791 2 (25.0) 18 (14.9) 0.609
Edmondson-Steiner grade (III, IV) 28 (75.7) 154 (70.6) 0.694 22 (75.9) 73 (75.3) 1.000 6 (75.0) 81 (66.9) 1.000
Vascular invasion
Major vascularf 5 (13.5) 13 (6.0) 0.154 4 (13.8) 9 (9.3) 0.494 4 (50.0) 43 (35.5) 0.461
Microvascular 23 (62.2) 84 (38.5) 0.011 19 (65.5) 41 (42.3) 0.035 1 (12.5) 4 (3.3) 0.278
Pathologic T categoryg(pT3, pT4) 7 (18.9) 25 (11.5) 0.017 6 (20.7) 15 (15.5) 0.150 1 (12.5) 10 (8.3) 0.566
Pathologic N categoryg(N1)
(n  219)
3 (9.4) 0 (0) 0.003 2 (8.0) 0 (0) 0.056 1 (14.3) 0 (0) 0.061
Intratumoral fibrous stroma (present) 6 (16.2) 14 (6.4) 0.051 8 (27.6) 20 (20.6) 0.451 3 (37.5) 28 (23.1) 0.398
Immunohistochemistry
CAIX 29 (78.4) 97 (44.5) <0.001 — — — — — —
K19 16 (43.2) 32 (14.7) <0.001 15 (51.7) 23 (23.7) 0.006 1 (12.5) 9 (7.4) 0.485
EpCAM 20 (54.1) 60 (27.5) 0.002 22 (75.9) 43 (44.3) 0.003 3 (37.5) 40 (33.1) 1.000
uPAR 20 (54.1) 53 (24.3) 0.001 18 (62.1) 31 (32.0) 0.005 2 (25.0) 22 (18.2) 0.642
Ezrin 25 (67.6) 80 (36.7) 0.001 22 (75.9) 48 (49.5) 0.018 3 (37.5) 32 (26.4) 0.682
p53 20 (54.1) 44 (20.2) <0.001 14 (48.3) 24 (24.7) 0.021 6 (75.0) 20 (16.5) 0.001
Smad2/3 19 (51.4) 15 (6.9) <0.001 16 (55.2) 12 (12.4) <0.001 3 (37.5) 3 (2.5) 0.003
Ki-67 labeling index (%) 9.9 (0–44.1) 2.3 (0–50.9) <0.001d 10.2
(0.1–44.1)
3.9 (0–50.9) 0.064d 6.9 (0–19.9) 1.3 (0–39.4) 0.094d
Mitotic index (/10 high-power fields) 12 (0–116) 5 (0–66) <0.001d 15 (0–70) 8 (0–63) 0.074d 7 (1–116) 4 (0–66) 0.024d
Background liver fibrosis (n  252)h 0.160e 0.639e 0.160e
F0-F1 36 (16.7) 7 (18.9) 5 (17.2) 18 (18.9) 2 (25.0) 18 (15.0)
F2-F3 66 (30.7) 8 (21.6) 6 (20.7) 29 (30.5) 2 (25.0) 37 (30.8)
F4 113 (52.6) 22 (59.5) 18 (62.1) 48 (50.5) 4 (50.0) 65 (54.2)
Recurrence (%) 23 (62.2) 129 (59.2) 0.715 17 (58.6) 60 (61.9) 1.000 6 (75.0) 69 (57.0) 0.468
aFigures are shown in n (%) for frequency data, and median (range) for continuous variables.
bOnly cases with the complete set of immunohistochemical stain data (n  255) were analyzed.
cFisher’s exact test, unless otherwise stated (d, e).
dStudent t-test.
eChi-square test.
fInvasion of major branch of hepatic vein or portal vein.
gAJCC TNM staging system, 8th Edition.
hFibrosis data not available for three cases.
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and YAP and TAZ expression was co-localized in the tumor
cells for the 13 TAZ-positive HCC cases. There was no significant
difference in YAP or TAZ expression frequency according to
the HCC etiology. The complete set of immunohistochemical
stain data for all ten antibodies was obtained for 255 cases due to
tissue core loss, and therefore, 255 cases were enrolled for
subsequent analysis. Of the 255 HCCs, YAP and TAZ
expression were seen in 34 (13.3%) and 11 (4.3%) cases, and
the positive correlation between YAP and TAZ expression was
still observed (p < 0.001).
YAP/TAZ Expression is Associated with
Aggressive Clinicopathological Features,
Hypoxia and Stemness
As a whole, YAP positivity in HCC was associated with
significantly more frequent microvascular invasion (p  0.015),
a tendency for more frequent portal vein invasion (p  0.059) and
significantly more frequent intratumoral fibrous stroma (p 
0.035). The proliferation rates were significantly higher in
YAP-positive HCCs [mitotic index (p  0.020) and Ki-67
labeling index (p < 0.001)]. YAP-positive HCCs demonstrated
more frequent K19 (p < 0.001) and EpCAM (p  0.001)
expression, and more frequent CAIX expression (p < 0.001).
Serum AFP levels were higher in YAP-positive HCCs (p  0.065),
although not statistically significant.
TAZ expression was also associated with more frequent
intratumoral fibrous stroma (p  0.046), and significantly
increased proliferative activity [mitotic index (p  0.011 and
Ki-67 labeling index (p < 0.001)]. Similarly to YAP-positive
HCCs, TAZ-positive HCCs demonstrated more frequent K19
(p  0.007) and CAIX (p  0.034) expression. EpCAM expression
was also more frequent in TAZ-positive HCCs, although not
statistically significant (p  0.057).
As there was a significant positive correlation between YAP
and TAZ expression status and the clinicopathological features
were similar for YAP-positive and TAZ-positive HCCs, we
continued our analysis by grouping HCCs expressing YAP
and/or TAZ, resulting in 37 (14.5%) YAP/TAZ-positive HCCs
and 218 (85.5%) YAP/TAZ-negative HCCs (Table 2). After
grouping, YAP/TAZ-positive HCCs were significantly
associated with higher serum AFP levels (p  0.024), more
frequent microvascular invasion (p  0.011), higher T stage
(p  0.017) and lymph node metastasis (p  0.003). YAP/
TAZ-positive HCCs were significantly associated with frequent
stemness-related marker expression (K19, p < 0.001; EpCAM, p 
0.002) and frequent CAIX expression (p < 0.001). YAP/TAZ-
expression was also associated with more frequent expression of
EMT-related markers (uPAR: p  0.001, ezrin: p  0.001). In
addition, p53 expression was significantly more frequent in YAP/
TAZ-positive HCCs (p < 0.001), and smad2/3 expression was also
increased in YAP/TAZ-positive HCCs (p < 0.001), suggesting an
FIGURE 2 | The staining distribution of YAP, TAZ and CAIX in a whole tissue section of a hepatocellular carcinoma (upper row). YAP expression was strong in
intensity and easily recognized at low power (left). TAZ expression was focal, but co-localized with YAP expression (middle). CAIX expression was strong in intensity
and patchy, and were co-localized with YAP/TAZ expression in most cases (right). The boxed areas in the upper row are demonstrated at ×200 magnification in the
lower row. The inset in the lower row is a ×400 magnification picture demonstrating the nuclear staining for TAZ.
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association between YAP/TAZ positivity and the TGF-β signaling
pathway.
To evaluate the distribution of YAP, TAZ and CAIX
expression in HCCs in more detail, we selected 10 HCCs from
the same tissue microarray cohort that expressed both YAP and
TAZ, and stained these tumors for YAP, TAZ and CAIX on whole
tissue sections (Figure 2). YAP expression was diffuse
homogeneous in 2 cases, while the remaining 8 cases showed
patchy expression. TAZ expression was focal in all 10 cases, and
frequently localized at the periphery of the tumor cell nests.
Although TAZ expression was focal, they were co-localized with
YAP; TAZ-positive cells were also YAP-positive in the 10 whole
tissue sections tested. CAIX expression was observed in 8 of the
10 YAP/TAZ-positive HCCs, and CAIX staining distribution was
patchy in all 8 cases. CAIX expression was co-localized with YAP/
TAZ expression in 7 out of the 8 CAIX-positive cases; however, in
one case, CAIX expression was not co-localized with YAP or TAZ
expression.
Clinicopathological Significance of YAP/
TAZ Expression in HCCs According to
Hypoxia Marker Status
In order to explore the relationship between hypoxia and YAP/
TAZ in HCC, CAIX-positive and CAIX-negative HCCs were
analyzed separately. The results are summarized in Table 2 and
Figure 3. Interestingly, for CAIX-negative HCCs, the expression
status of YAP/TAZ had no associations with the expression status
of stemness-related or EMT-related markers. On the other hand,
for CAIX-positive HCCs, YAP/TAZ expression was significantly
associated with K19 (p  0.006), EpCAM (p  0.003), uPAR
(p  0.005) and ezrin (p  0.018) expression.
Smad2/3 and p53 expression status was correlated with YAP/
TAZ status for both groups, regardless of hypoxia marker status.
Similarly, mitotic indices were higher in YAP/TAZ-positive
HCCs regardless of CAIX status, although statistically
significant only in the CAIX-negative group (p  0.024). Ki-67
labeling indices were higher in YAP/TAZ-positive HCCs
regardless of CAIX status, but statistical significance was not
reached (CAIX + HCC: p  0.064, CAIX - HCC: p  0.094).
As for the clinicopathological features, more frequent
microvascular invasion (p  0.035) was observed in YAP/
TAZ-positive HCCs, along with tendencies for higher serum
AFP levels (p  0.068) and frequent lymph node metastasis
(p  0.056), in the CAIX-positive group. There were no
differences in any of the clinicopathological features according
to YAP/TAZ expression status in the CAIX-negative group,
except for a tendency for more frequent lymph node
metastasis (p  0.061). No significant difference in patient
survival (overall or disease-free survival) according to YAP or
TAZ expression status was demonstrated, regardless of hypoxia
status.
DISCUSSION
In this study, we demonstrate that although the expression of
YAP/TAZ in HCCs is associated with “stemness,” EMT and
aggressive clinicopathological features as previously reported, this
relationship is seen only in HCCs with hypoxia marker
FIGURE 3 | Summary of the characteristics of YAP/TAZ-positive HCCs with relation to hypoxia marker expression status (hematoxylin-eosin stain and CAIX, K19,
EpCAM, uPAR and ezrin immunohistochemistry, ×200).
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expression. The relationship between tumor hypoxia, YAP/TAZ
and stemness is still not well understood. Hypoxia is an important
condition for the tumor microenvironment, as it can induce
cancer growth, metastasis, angiogenesis, EMT and
chemoresistance [18]. Wei et al. demonstrated in their in vitro
and human tissue study of pancreatic cancer that hypoxia
deactivated the Hippo pathway, induced the nuclear
translocation of YAP and promoted the activation of Snail
transcription in the ductal adenocarcinoma cell lines [20].
Interestingly, in an in vitro study by Yan et al., hypoxic
conditions reduced the expression of the activated form of
YAP, while TAZ was induced by hypoxia, suggesting that YAP
and TAZ were differentially regulated by hypoxic conditions [23].
In this study, we did not find differences between YAP and TAZ
protein expression status when CAIX-positive and CAIX-
negative HCCs were analyzed separately. Nevertheless, it is
interesting that the expression of YAP and/or TAZ in HCCs
was associated with features of aggressive behavior, stemness and
EMT only in the presence of CAIX expression, suggesting that the
action of YAP/TAZ may be regulated by the hypoxic
microenvironment in HCCs.
Another interesting finding in our study is the positive
correlation between YAP/TAZ expression, the presence of
intratumoral fibrous stroma and the expression of stemness-
related markers. YAP expression has previously been
demonstrated in a substantial proportion of K19+/EpCAM +
HCCs and combined hepatocellular-cholangiocarcinomas [11,
15], and it was therefore suggested that the Hippo signaling
pathway may be involved in the acquisition of stemness features
of HCCs and combined hepatocellular-cholangiocarcinomas
[15]. Notably, TGFβ has been recently shown to interact with
Hippo signaling pathways to stimulate regenerating hepatocytes
to undergo an EMT-like response [24]. In addition, TGFβ
signaling pathway upregulation has been demonstrated in
HCCs with abundant fibrous stroma, such as scirrhous HCC;
these tumors are frequently associated with stemness-related
marker expression [25]. We observed a positive correlation
between YAP/TAZ and smad2/3 expression in both CAIX-
positive and CAIX-negative HCCs, suggesting that, regardless
of hypoxia status, TGFβ signaling may play an important role in
the fibrogenesis of HCCs by interacting with the Hippo signaling
pathway.
Despite the associations with clinicopathological features of
aggressive behavior, the presence of YAP/TAZ expression did not
appear to have prognostic significance in our study, even on
separately analyzing the CAIX-positive and negative HCCs.
There have been discrepancies regarding the prognostic value
of YAP and TAZ in the literature, and differences in the
interpretation methods (nuclear, cytoplasmic or
nucleocytoplasmic) for YAP and TAZ expression has been
suggested to be a reason for this discrepancy [11, 14, 26–28].
We interpreted only nuclear staining as positive for YAP and
TAZ as reported by Van Haele et al. [11].
From the therapeutic point of view, several small molecule
inhibitors targeting the Hippo signaling pathway have been found
to be effective in treating various malignancies. For example,
dasatinib, which inhibits the nuclear localization of the YAP/TAZ
complex, and verteporfin, which disrupts the formation of the
YAP-TEAD complex, are currently used in clinical trials for
chronic myeloid leukemia and metastatic breast cancer,
respectively [29]. Verteporfin has also been demonstrated to
suppress the early stages of hepatocarcinogenesis [30]. As we
found that the biological behavior of YAP/TAZ-expressing HCCs
may depend on the expression status of CAIX, we could carefully
suggest that CAIX could potentially be used as a marker of
response to drugs targeting the Hippo pathway in HCCs.
However, this would need validation with functional studies
and also large scale tissue-based studies in independent patient
cohorts.
In conclusion, YAP and TAZ expression in HCC are
associated with aggressive clinicopathological features,
stemness and EMT, and this relationship is seen in HCCs
with hypoxia marker expression. This suggests that the effect
of Hippo signaling pathway deregulation in HCCmay depend on
the presence or absence of a hypoxic microenvironment, and that
hypoxia marker expression status should be taken into account
when considering the use of YAP/TAZ as markers of aggressive
biologic behavior in HCC.
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